Key pathophysiologic mechanisms include: Mucosal barrier dysfunction: Impaired epithelial tight junctions allow bacterial translocation, triggering innate immune activation T-helper cell dysregulation: Predominantly Th1 and Th17 pathways drive chronic inflammation via TNF-, IL-12, IL-23 the basis for biologic therapy targets Transmural inflammation: Unlike UC (mucosal only), CD involves all layers: mucosa submucosa muscularis propria serosa Granuloma formation: Non-caseating granulomas are pathognomonic but present in only ~3050% of biopsies Fibrosis and stricture: Chronic inflammation activates myofibroblasts collagen deposition luminal narrowing obstructive symptoms Fistula formation: Transmural ulcers penetrate serosa form sinus tracts connect to adjacent bowel, bladder, vagina, or skin 7
Step 4: Do not shake
We take the time to discuss our approach to diagnosis, recommend the appropriate frequency of injections, and explain how we monitor your progress to ensure optimal results
We will gladly answer your questions, take our time and help you determine if this is the right treatment for you
The reconstituted peptide shelf life guide provides specific timelines for different peptides
Others who choose to take pills or subdermal supplements may notice a more gradual effect, sometimes taking a few weeks before their symptoms improve
